Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEXTER
NCT07800910Phase 1Not yet recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in sleep disorder, circadian rhythm sleep disorder (CRSD) and neurodegenerative disease comparing Sublingual Dexmedetomidine First with Placebo First (2 arms). Primary endpoints: Number of Participants With Adverse Events, Proportion of Participants Completing the Study and 3 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
sleep disordercircadian rhythm sleep disorder (CRSD)neurodegenerative disease
Beyond the preview
Go deeper on NCT07800910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07800910.